Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02861573
Title Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)
Recruitment Recruiting
Gender male
Phase Phase I
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.

prostate adenocarcinoma


Dexamethasone + Docetaxel + Pembrolizumab + Prednisone

Olaparib + Pembrolizumab

Enzalutamide + Pembrolizumab

Age Groups: adult | child
Covered Countries USA | ITA | FRA | DEU | CAN | AUT

No variant requirements are available.